Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
about
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIVSafety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies.Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.Pathophysiology and management of cardiovascular disease in patients with HIVThe effect of recombinant human growth hormone with or without rosiglitazone on hepatic fat content in HIV-1-infected individuals: a randomized clinical trial.Risk of coronary heart disease in patients with HIV infection.The past 10 years-new hormones, new functions, new endocrine organs.Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy.Heart fat in HIV: marker or mediator of risk?Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence.Endocrinological aspects of HIV infection.Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection.NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?
P2860
Q28079826-172AB75D-66E9-4C39-97A9-A57118111D64Q33803331-8E94D044-413B-418B-A91B-8F68D9014DC0Q34540703-54DCE9F7-05B7-40AB-BFE3-D72C4A1ED886Q35072510-A8814CCE-BD65-4F0A-8B11-13A305F54EB1Q35803315-9529EE9D-4BC2-46CB-A655-ACCD98D53B90Q37038775-2E3E0574-E41C-434B-8ED5-4CB922C07DA7Q37415273-7AF73439-7AE9-480E-870F-9CFE8B904CC9Q38261508-9C3A7EE4-BB96-46DD-A525-AC078B77183CQ38577490-CFE1D979-6C94-4CC9-908E-860818B1428CQ38612748-816BCFBD-8DA8-4943-AD04-A1D7CD9BC8B1Q38614025-A41F6A43-B633-4A75-B51E-C90AAA6A13CAQ38630822-E957BDFC-F94E-4755-A020-FDABC9C0C493Q38931905-870E9159-98CC-4BA5-A21A-6A799F0E73DFQ47219853-085AE72E-BDFA-4486-8AAA-138EB11E05DAQ47795127-2E208698-4E06-4DAE-9CD2-18309672EBA9Q47891372-A1F7DBEC-070C-4DD2-9BFF-42C8F7385DA9Q54232638-B9E73662-11B6-4334-B3A0-0E2F7C683053
P2860
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Effect of tesamorelin on visce ...... n: a randomized clinical trial
@ast
Effect of tesamorelin on visce ...... n: a randomized clinical trial
@en
type
label
Effect of tesamorelin on visce ...... n: a randomized clinical trial
@ast
Effect of tesamorelin on visce ...... n: a randomized clinical trial
@en
prefLabel
Effect of tesamorelin on visce ...... n: a randomized clinical trial
@ast
Effect of tesamorelin on visce ...... n: a randomized clinical trial
@en
P2093
P2860
P356
P1476
Effect of tesamorelin on visce ...... n: a randomized clinical trial
@en
P2093
Karen L Branch
Martin Torriani
Meghan N Feldpausch
Steven K Grinspoon
P2860
P304
P356
10.1001/JAMA.2014.8334
P407
P577
2014-07-01T00:00:00Z